nox

Diphenyleneiodonium chloride (DPI)(DPI) is an irreversible inhibitor of iNOS and eNOS (IC50 values of 50 nM and 0.3 μM, respectively),and displays broad-spectrum bactericidal activity.

ML-090 is NOX1-specific inhibitor(IC50 = 90 nM) which is >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50s >10 μM).

APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with inhibition constants (Kis) of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4, respectively, and it effectively prevents kidney injury.

GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption. GSK2795039 decreases apoptosis. GSK2795039 is an inhibitor of NADPH oxidase 2 (NOX2) (pIC50: 6 in different cell-free assays).

VAS 3947 is a specific inhibitor of NADPH oxidase (NOX).VAS 3947 has a potent anti-platelet effect, inducing apoptosis through UPR activation, mainly due to protein aggregation and misfolding, independent of anti-NOX activity.

VAS2870 is an inhibitor of NADPH oxidase (NOX).

Setanaxib (GKT137831) is a potent, specific dual NADPH oxidase (NOX1/4) inhibitor.

GLX351322 is NADPH Oxidase 4 Inhibitor with IC50 of 5 μM.

GKT136901 (AK120765) is an inhibitor of NOX1/4.It acts as Selective and Direct Scavenger of Peroxynitrite

NOX-6-18 (GPR132-B-160) is a highly potent and selective GPR132 antagonist with insulinotropic activity that modulates macrophage reprogramming in pancreatic islets and reduces weight gain.

NOX5-IN-1 (Compound 13) is a selective inhibitor of NADPH oxidase 5 (NOX5), with an IC50 of 0.30 μM. It effectively inhibits NOX5-dependent ROS production in freestyle293 cells (EC50: 0.86 μM). NOX5-IN-1 is applicable for research into NOX-related diseases, including cardiovascular conditions, cancer, and neuroinflammation.

NOX5-IN-2 (Compound 17) is a selective inhibitor of NADPH oxidase 5 (NOX5) with an IC50 value of 0.70 μM. It effectively suppresses NOX5-dependent ROS production in freestyle293 cells, exhibiting an EC50 of 1.8 μM. NOX5-IN-2 is useful for researching NOX-related diseases, such as cardiovascular disorders, cancer, and neuroinflammation.

NOX2-IN-2 diTFA (compound 33) is an effective inhibitor of NOX2, targeting the p47phox-p22phox protein-protein interaction with a Ki of 0.24 μM. This compound effectively suppresses the production of ROS generated by NOX2 in cells.

NOX4-IN-1 (Compound 14m) is an inhibitor of NADPH oxidase 4 (NOX4) that reduces the production of reactive oxygen species (ROS). It also inhibits the TGF-β1/Smad signaling pathway, leading to decreased expression of fibrosis-related proteins. Additionally, NOX4-IN-1 impedes the migration of NRK-49F cells.

NOX2-IN-2 (compound 33) is a potent inhibitor of NOX2, disrupting the p47phox-p22phox protein-protein interaction with a dissociation constant (Ki) of 0.24 μM, and effectively suppressing reactive oxygen species (ROS) production from NOX2 in cellular contexts [1].

NOX2-IN-1 (compound 10) is an inhibitor of nicotinamide adenine dinucleotide phosphate oxidase isoform 2 (NOX2), disrupting the p47phox-p22phox protein-protein interaction with high binding affinities and potent activity in cellular assays [1].

NOX2-IN-3 (compound 3), functioning as an inhibitor of NOX2 (NADPH Oxidase 2), enhances the sensitivity of tumor cells to MRTX1133 [1].

Norathiol (N-methyl-N-dithiocarboxyglucamine) is an antidote for cadmium poisoning and a metal chelator that promotes the excretion of 109Cd and can be used in the treatment of cadmium poisoning.

MDCG sodium (N-methyl-N-dithiocarboxyglucamine sodium) is a metal chelator that promotes biliary excretion of Cd.

Lexaptepid Pegol sodium is a PEGylated L-oligonucleotide capable of binding to hepcidin and inhibiting its activity.

Thr101, also known as NOX Inhibitor VII, is a dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9. Thr101 is also a NOX inhibitor.

Etonitazene N-oxide (EtN-NOX) is a metabolite of the opioid compound Etonitazene.

Amlexanox (AA673) is an anti-aphthous ulcer drug. Amlexanox inhibits the synthesis and release of inflammatory mediators, including leukotrienes and histamine, from mast cells, neutrophils, and mononuclear cells. Amlexanox also acts as a leukotriene D4 antagonist and a phosphodiesterase inhibitor. Amlexanox decreases the time ulcers take to heal as well as the pain associated with the ulcers.

5-Iodo-indirubin-3'-monoxime is a potent inhibitor of GSK-3β, CDK5/P25, and CDK1/cyclin B, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20, and 25 nM).